Moderna requests emergency FDA authorization for COVID-19 vaccine

Article

Moderna announced yesterday its plan to apply for emergency FDA authorization for its COVID-19 vaccine candidate.

Moderna also reported that the primary efficacy analysis of its phase 3 COVE study of mRNA-1273 demonstrated a high efficacy rate of 94.1%, with a 100% efficacy rate against severe COVID-19. A total of 196 cases of COVID-19, including 30 severe cases, among 30,000 participants were included in the analysis.

Vaccine efficacy was initially reported at the first interim analysis with a total of 95 cases based on pre-specified success criteria on efficacy. Today’s primary analysis was based on the 195 cases, of which 185 cases were observed in the placebo group versus 11 cases in the mRNA-1273 group. The primary end point is based on the analysis of COVID-19 cases confirmed and adjudicated starting 2 weeks following the second dose of the vaccine.

Continue reading this article on Drug Topics.

Recent Videos
COVID-19 Therapy Roundtable: Focusing on inpatient care
COVID-19 Therapy Roundtable: Defining the virus today and treatment options
The importance of maternal vaccination | Image Credit: nfid.org.
Jeanette Carpenter, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.